NCT01449019

The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)

The Contribution of Glucagon-like Peptide 1 (GLP-1) to the Entero-insulinar Axis in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Ludwig-Maximilians - University of Munich · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to determine the contribution of endogenous Glucagon-like peptide 1 (GLP-1) to the postprandial secretion of insulin and glucagon and the incretin effect in healthy subjects and patients with type 2 diabetes mellitus (T2DM).

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	exendin(9-39)amide	intravenous infusion of exendin(9-39)
DRUG	saline	intravenous infusion of saline
OTHER	duodenal meal	duodenal perfusion of a meal
OTHER	duodenal saline	duodenal perfusion of saline

Timeline

• Start date: 2006-12-01
• Primary completion: 2007-08-01
• Completion: 2010-07-01
• First posted: 2011-10-07
• Last updated: 2011-10-07

Locations

2 sites across 1 country: Germany